OptimizeRx resumed with a Buy at B. Riley

B. Riley analyst Neil Chatterji resumed coverage of OptimizeRx with a Buy rating and $30 price target, which represents 70% upside. OptimizeRx is a leading provider of point-of-care technology solutions to improve both patient access and adherence to treatment, the analyst tells investors in a research note. The firm sees a favorable risk/reward setup with the shares down 65% in 2022 as the company looks to execute on its core business with large pharma partners and return closer to the 20% growth rates.